Immuneering
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
245 Main St Fl 2, Cambridge, Massachuset...Phone Number
(617) 500-8080Website
www.immuneering.comRevenue
$14.4 MillionStock Symbol
IMRXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Immuneering
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneerings lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The companys development pipeline also includes several early-stage programs.Explore more
Immuneering Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immuneering your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Immuneering, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Immuneering recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Immuneering
Product Launch: Get notified when Immuneering launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Immuneering has new funding data
Check if Immuneering has recently received funding, and reach out quickly before it becomes old news!
Check out if Immuneering is spiking on competitors!
Click to see if Immuneering had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Immuneering
Compare insights from companies similar to Immuneering, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immuneering is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immuneering is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immuneering.
Immuneering financials insights
Gather financial insights about Immuneering, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$20M
2021
Series B
$62M
Share Placement
$112.5M
2025
Private Equity
$25M
Immuneering Tech Stack
A closer look at the technologies used by Immuneering
See more technologies
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Immuneering News & Media
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic CanImmuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus ChemotherapyImmuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Reports First Quarter 2026 Financial Results and Provides Business UpdatesImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immuneering
Sign Up For FreeTo access detailed company insights
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneerings lead product candidate, IMM-1-... Read More
